R
ecent guidelines from the United States Preventive Services Task Force (USPSTF) say that there is insuffi cient evidence to recommend screening for obstructive sleep apnea in people who have no symptoms of it. [1] [2] [3] The USPSTF committee systematically reviewed the evidence, sifting through 1,315 articles, 3 and found no randomized controlled trials that compared screening with no screening in adults who have no symptoms (or no recognized symptoms) of obstructive sleep apnea. Conclusion: "The current evidence is insuffi cient to assess the balance of benefi ts and harms of screening for [obstructive sleep apnea] in asymptomatic adults." 1 This is logical, rigorous, and evidencebased. However, the conclusions might be misinterpreted and need to be put into context.
■ SCREENING IS WARRANTED IF PATIENTS HAVE SYMPTOMS
First, note that the USPSTF is referring to people who have no symptoms. The American Academy of Sleep Medicine has issued recommendations about screening and diagnostic testing in people who do have symptoms, 4 in whom it is important to pursue screening and diagnostic testing.
Symptoms of obstructive sleep apnea include excessive daytime sleepiness, fatigue, drowsy driving, disrupted or fragmented sleep, nocturia, witnessed apnea, snoring, restless sleep, neurocognitive defi cits, and depressed mood. Treating it improves these symptoms, as clinical trials have shown unequivocally and consistently. 5 Moreover, the third edition of the International Classifi cation of Sleep Disorders defi nes obstructive sleep apnea as an obstructive apnea-hypopnea index of 15 or more events per hour even in the absence of symptoms. This threshold recognizes the risk of adverse health outcomes observed in population-based studies (ie, in participants recruited irrespective of symptoms). 6 
■ ABSENCE OF EVIDENCE, NOT EVIDENCE OF ABSENCE
Second, the absence of suffi cient evidence cited by the USPSTF does not necessarily mean that screening for obstructive sleep apnea in asymptomatic people is not benefi cial-it has just not been systematically studied. There was insuffi cient evidence available to make a recommendation to allocate resources to screen all patients irrespective of symptoms. The Sleep Heart Health Study suggested that few people with obstructive sleep apnea were diagnosed with it and that even fewer were treated for it. 7 More recent data indicate that this underdiagnosis persists and is more pervasive in underserved minority groups. 8, 9 ■ SCREENING VS CASE-FINDING Moreover, screening is not the same as casefi nding. The purpose of screening, as defi ned 50 years ago by Wilson and Jungner in a report for the World Health Organization, is "to discover those among the apparently well
The fi nding of absence of evidence of benefi t could be misinterpreted SCREENING FOR OBSTRUCTIVE SLEEP APNEA who are in fact suffering from disease." 10 Case-fi nding, on the other hand, focuses on those suspected of being at risk of the disease. In the case of obstructive sleep apnea, this is a lot of people. The overall prevalence of obstructive sleep apnea is about 26% by one estimate, 11 and many more people have risk factors for it. For example, in one study, 69% of patients presenting to a primary care clinic were overweight or obese, 12 and many primary care patients have diseases that obstructive sleep apnea can exacerbate. One can therefore argue that in clinical practice, testing for obstructive sleep apnea is more like case-fi nding than screening-most patients that you see have unrecognized symptoms of it or risk factors for it.
■ CRITERIA FOR A GOOD SCREENING TEST
Principles for screening outlined by Wilson and Jungner 10 were: • The condition we are trying to detect should be important • There should be an accepted treatment for it • Facilities for diagnosis and treatment should be available • Testing should be acceptable to the population • There should be cost benefi t to the expense of case-fi nding • There should be an agreed-upon policy on whom to treat as patients. Screening for obstructive sleep apnea meets many of these criteria.
Obstructive sleep apnea is important
Solid evidence exists that obstructive sleep apnea exerts a bad effect on health and quality of life. Population-based studies that enrolled participants irrespective of symptoms indicate that the risk of death is about twice as high in those with severe obstructive sleep apnea as in those without, and treatment exerts benefi t especially in those with cardiovascular risk. 13, 14 Therefore, the criterion for screening that says the disease must be important is met.
Pathophysiologic pathways by which obstructive sleep apnea causes harm include intermittent hypoxia, hypercapnia, intrathoracic pressure swings, and autonomic nervous system fl uctuations.
Treatment is benefi cial
The seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure recognized obstructive sleep apnea as a cause of hypertension. 15 Treating obstructive sleep apnea lowers blood pressure, which in turn improves cardio vascular outcomes. Effects are most pronounced in those with resistant hypertension. The reduction in blood pressure is only about 2 to 3 mm Hg, but this translates to a 4% to 8% reduction in future risk of stroke and coronary heart disease. 16, 17 The Continuous Positive Airway Pressure Treatment of Obstructive Sleep Apnea to Prevent Cardiovascular Disease multicenter randomized clinical trial investigated the impact of treating obstructive sleep apnea with continuous positive airway pressure (CPAP) compared with usual care. 18 Although no statistically signifi cant difference was seen in the composite cardiovascular outcome, propensity-score analysis in the subgroup adherent to CPAP demonstrated a lower composite of cerebral events in those who used CPAP for at least 4 hours a day.
The fi ndings from this trial are diffi cult to interpret for several reasons. Adherence to CPAP was suboptimal, the severity of obstructive sleep apnea might not have been bad enough to permit observation of a signifi cant treatment effect, and the generalizability of the fi ndings is unclear, given that many of the participants were from underresourced regions. 19 In a meta-analysis of cohort studies comprising more than 3 million participants, Fu et al found that the cardiovascular mortality rate was 63% lower in those with obstructive sleep apnea using CPAP than in untreated patients. 20 
■ APPLY CLINICAL JUDGMENT
Overall, the USPSTF report is intended to guide healthcare decision-makers. However, it includes a caveat to not substitute the fi ndings for clinical judgment and to interpret the fi ndings in the context of collateral pertinent information. 2 Although no high-quality data exist to support or refute global screening for obstructive sleep apnea in the primary care setting, The USPSTF fi ndings should not substitute for clinical judgment MEHRA AND FOLDVARY-SCHAEFER the high prevalence of this disease and its detrimental effects on health and quality of life if left untreated should not be dismissed.
Arguably, most patients who present to primary care clinics are not healthy, are not free of symptoms, and are at risk of obstructive sleep apnea because they are obese. Testing for it is therefore more like case-fi nding than screening.
In view of the serious consequences of obstructive sleep apnea, we should view the situation as an opportunity to examine the impact of screening. Perhaps using electronic medical records, we could collect sleep-specifi c measures, implement case-fi nding strategies, and perform pragmatic clinical trials to inform and guide optimal and cost-effective screening approaches.
Patients with common disorders such as obstructive sleep apnea are often considered asymptomatic until asked about symptoms. Therefore, careful review of systems incorporating sleep health is important, particularly as patients do not typically volunteer this information. Obtaining this history does not necessarily fall under the USPSTF's recommendation not to screen.
Future efforts should focus on leveraging the electronic medical record platform to collect sleep-specifi c measures, implementing case-fi nding strategies, and performing pragmatic clinical trials in the primary care setting to inform and guide optimal and cost-effective approaches to screening.
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